Your session is about to expire
← Back to Search
SABR for Metastatic Prostate Cancer (ANCHORProstate Trial)
Phase 2
Recruiting
Research Sponsored by Centre hospitalier de l'Université de Montréal (CHUM)
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 5 years
Awards & highlights
ANCHORProstate Trial Summary
This trialwill investigate if SABR treatment helps men with metastatic prostate cancer live longer. 80 patients will be randomly selected to receive this experimental treatment.
Who is the study for?
This trial is for men with metastatic prostate cancer who are part of the PERa registry and have shown the best possible response to standard treatments, as seen by stable PSA levels. They should be able to perform daily activities (ECOG 0-2) and have a PSA greater than 0.2 ng/mL. Only those with 1-5 areas of cancer detectable on PSMA-PET scans that can be targeted by SABR will qualify.Check my eligibility
What is being tested?
The ANCHOR-Prostate trial is testing whether adding a type of precise radiation therapy called SABR (Stereotactic Ablative Radiotherapy) after maximum response from usual drug treatments can help control prostate cancer better. The main goal is to see if patients remain free from disease progression one year after treatment.See study design
What are the potential side effects?
While specific side effects are not listed here, SABR commonly includes risks such as fatigue, skin reactions in treated areas, urinary issues like increased frequency or discomfort, bowel changes including diarrhea or rectal bleeding, and potential impacts on sexual function.
ANCHORProstate Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~5 years
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
FFS
Secondary outcome measures
HRQoL
Time to progression
Toxicity
ANCHORProstate Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: SABR consolidationExperimental Treatment1 Intervention
Group II: Control - no SABR consolidationActive Control1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
SABR
2013
Completed Phase 2
~70
Find a Location
Who is running the clinical trial?
Centre hospitalier de l'Université de Montréal (CHUM)Lead Sponsor
366 Previous Clinical Trials
129,557 Total Patients Enrolled
5 Trials studying Prostate Cancer
2,109 Patients Enrolled for Prostate Cancer
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have 1-5 areas of cancer visible on a PSMA-PET scan that can be treated with targeted radiation.Not applicable.I can take care of myself and perform daily activities.My prostate cancer has spread, and my PSA levels have been stable after starting standard treatment.
Research Study Groups:
This trial has the following groups:- Group 1: Control - no SABR consolidation
- Group 2: SABR consolidation
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Are there any remaining vacancies in this test cohort?
"As per the clinicaltrials.gov listing, this medical trial is currently accepting applicants. The original post was published on December 30th 2022 and the record was recently amended on January 31st 2023."
Answered by AI
What potential risks do patients face when undergoing SABR consolidation therapy?
"As this is a Phase 2 clinical trial and there are some established safety protocols but no evidence of efficacy, SABR consolidation received an estimate score of two."
Answered by AI
How many participants have been enrolled in this medical experiment?
"Affirmative. The information hosted on clinicaltrials.gov reveals that this experiment is actively recruiting participants, having been posted on December 30th 2022 and recently updated on January 31st 2023. Currently, 80 volunteers are needed at one medical centre."
Answered by AI
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger